Minimally Invasive Glaucoma Surgery (MIGS) Devices Market By Device Type (Stents {Intraocular stents, Ab-interno stents}, Implants {Trabecular implants, Suprachoroidal implants}, Laser Systems {Selective laser trabeculoplasty (SLT), Other laser devices}, Goniotomy Devices), By Target (Trabecular Meshwork Bypass, Suprachoroidal Space, Subconjunctival Space, Schlemm’s Canal, Others), By Glaucoma Type (Primary Open-Angle Glaucoma (POAG), Angle-Closure Glaucoma, Secondary Glaucoma, Normal Tension Glaucoma, Others), By End-User (Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market accounted for USD 586.3 Million in 2024 and is expected to reach USD 1,045.6 Million by 2035, growing at a CAGR of around 5.4% between 2025 and 2035. The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market focuses on devices that assist in treating glaucoma through operations that produce less tissue damage than conventional surgery and faster recovery. These devices commonly seek to reduce IOP by increasing the facility of aqueous humor or generating new exit routes. MIGS's eye-related goods include stents, implants, and micro-surgical equipment, which appear to be beneficial to patients and surgeons due to their safety and dependability. The rising incidence of glaucoma, together with the increasing acceptance of technical advances in surgery, is driving the expansion of this market.

Report Scope:

Market Dynamics

The increasing prevalence of glaucoma boosts demand for effective treatments.

Glaucoma is growing rapidly around the world, driving the need for Minimally Invasive Glaucoma Surgery (MIGS) Devices Market. Glaucoma is becoming increasingly common as the world's population grows and life expectancy rises, necessitating the development of new, more effective, and safer treatment regimens. MIGS offers quicker recovery times and fewer complications than open operations, appealing to both patients and surgeons. Further, there is growth in the field of technology that creates better and improved MIGS devices, making it easier to be effective. Other factors driving market expansion include an increase in glaucoma incidence and prevalence and a greater understanding of the need for effective treatments.

Many other educational establishments, including the American Academy of Ophthalmology, say that almost 3 million individuals in America suffer from glaucoma, which explains the necessity of effective treatment. Symptoms such as the growing movement in healthcare settings from a provider-centric to a patient-centric model would considerably aid the MIGS market's growth. In summary, the growing global population, the availability of contemporary technology, and more public awareness all contribute to the growth of the MIGS industry.

Patients prefer minimally invasive procedures due to quicker recovery.

The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market is driven by several factors. The rising incidence of glaucoma combined with an aging population necessitates the development of effective medicines. People have welcomed MIGS because of its benefits, which include a shorter healing time, fewer complications than traditional operations, and no discomfort. Surgical development and advancements in MIGS devices impact the popularity of the MIGS since they improve patients' quality of life. Furthermore, voluntary and increased sensitization among patients and healthcare providers raises awareness of the potential for these techniques to guide adoption. Improved reimbursement policies and ongoing research on MIGS are projected to drive market growth in the next few years.

Patients prefer minimally invasive procedures due to quicker recovery.

High procedure costs are a major factor in imposing restrictions on Minimally Invasive Glaucoma Surgery (MIGS), as they reduce the availability of innovative devices in emerging markets. The costs of MIGS procedures may include the MIGS devices, the surgical competence, and the relevant healthcare infrastructure. These expenditures can be too expensive in many low-income regions, leading to the use of routine surgery, which may be less effective but less expensive. However, because awareness and training in MIGS among healthcare providers remain low, the use of these technologies is likewise limited, which can contribute to insufficient access. Consequentially, while MIGS appears to be a promising method for glaucoma therapy due to shorter postoperative durations and fewer complications, its market is constrained by both economic and healthcare accessibility concerns.

Personalized medicine approaches can improve patient outcomes and satisfaction.

The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market indicates that enhancing patient-centered strategies through the system could highly value personalized medicine. Compared to traditional glaucoma operations, these devices present less invasive procedures and have a shorter rehabilitation stay and fewer sidelines. These glaucoma operations can be tailored to the specific demands of each patient, including the use of microcatheters and implantable devices, the patient's glaucoma severity, and overall health. Furthermore, as people are diagnosed with glaucoma and as the population ages, the demand for such remedies continues to grow. With the new trends in patient-centric care, MIGS can offer suitable care plans, better patient compliance and quality of life, and cost-efficient strategies for healthcare suppliers. Due to this compatibility with the concept of personalized medicine, MIGS is an attractive segment of the ophthalmic device industry.

Telemedicine integration facilitates early diagnosis and treatment planning.

The use of telemedicine in the field of ophthalmology has the potential to unlock growth in the Minimally Invasive Glaucoma Surgery (MIGS) Devices Market. Thus, because telemedicine allows patients to consult and be monitored remotely, glaucoma can be detected and treated early with MIGS equipment. This technology broadens patient options for specialized care and enhances treatment organization by allowing for remote assessments of patient statuses. Furthermore, engaging patients with 'any' telehealth enhances patient attendance and follow-up care compliance, making it important to MIGS surgery success. Future advancements will be based on increasing information on glaucoma and the efficacy of MIGS procedures, which will be aided by advances in device technology and the use of telemedicine to monitor patient results.

Industry Experts Opinion

 “I am truly excited to be part of Hexiris’ journey to advance the development of their new innovative MIGS device. I believe the device has the potential to improve patients’ lives while helping ophthalmologists enhance patient care, which is of paramount importance to me.”

• Dr. Paul Harasymowycz, renowned ophthalmologist and recognized innovator in MIGS techniques.

Segment Analysis

Based on the device type, the Minimally Invasive Glaucoma Surgery (MIGS) Devices Market is classified into Stents, Implants, Laser Systems, and Goniotomy Devices. Stents dominate the Minimally Invasive Glaucoma Surgery (MIGS) Devices Market. This is due to their efficacy in IOP management with fewer surgical problems, making them popular among patients and surgeons. Patients were informed that balloon stents have quicker recovery times and fewer complications than other surgical procedures, which boosts patient satisfaction. Furthermore, advancements in stent manufacturing are improving stent performance and thereby boosting their use. Stents are likely to dominate the MIGS market due to the increasing demand for devices that are less intrusive than shunts.

Based on the glaucoma type, the Minimally Invasive Glaucoma Surgery (MIGS) Devices Market is classified into Primary Open-Angle Glaucoma (POAG), Angle-Closure Glaucoma, Secondary Glaucoma, Normal Tension Glaucoma, and Others. Primary Open-Angle Glaucoma (POAG) is the dominant type of glaucoma in the Minimally Invasive Glaucoma Surgery (MIGS) market. This is probably due to the high number of POAG glaucoma, which constitutes the most common type of glaucoma globally. New MIGS devices are now emerging to fit the requirements of POAG patients, known to cause fewer complications and faster recovery than traditional surgeries. In this market, POAG is a key factor because it leads to innovation and investment by manufacturers. As awareness and screening continue to improve in this group, the need for optimal treatment is expected to rise again. Finally, POAG affects the market potential of the MIGS industry.

Regional Analysis

The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market in North America has substantial growth potential as glaucoma cases rise and surgeons shift to less invasive glaucoma surgery. Stakeholders in the market are developing relevant technologies to improve patient outcomes, resulting in a comprehensive classification of medical devices, including stents and drainage implants. The market is driven by an increasing incidence of glaucoma as the older population grows and improved knowledge of glaucoma management. Other institutions, such as the FDA, have provided regulatory clearances, facilitating the marketing of complicated MIGS products. Further, the incorporation of digital health solutions in surgical practices should close the gap in other surgical practices, making MIGS a significant segment of the global ophthalmic device market. There is a lot of activity in the form of strategic collaborations, mergers, and further R&D aimed at improving surgical effectiveness and device utilization.

The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market is the fastest growing in the Asia-Pacific region due to the rising frequency of glaucoma and the growing population of geriatrics. The top-ranked countries are Japan, China, and India, with increased technology and healthcare facilities that have improved the availability of MIGS procedures. The desire to use less invasive surgical solutions catalyzes developments in product design and performance on the side of both customers and providers. Besides, the rising trend for glaucoma management and the associated advantages of the technology push the MIGS market forward. Government incentives and funds for research and development are accelerating the market growth, which is predicted to position Asia Pacific as an important region globally.

Competitive Landscape

The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market is highly competitive, and major players are continuously entering into collaborations and innovating in products like Glaukos Corporation, Alcon, and AbbVie (Allergan). Glaukos remains ahead of rivals as it expands on its iStent technology, the latest FDA approval for the next-generation iStent inject W, which addresses patients’ issues by optimizing flow. The company has expanded into the CyPass Micro-Stent to reduce intraocular pressure, which poses a risk to patients. Further, the OMNI surgical system is developed by combining viscoelastic and microcatheter technologies, resulting in a one-stop solution for glaucoma therapy at Sight Sciences. These are innovative and promising efforts to reduce intrusive treatments and procedures to improve patient safety and dependability while also contributing to market expansion.

Minimally Invasive Glaucoma Surgery (MIGS) Devices Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In July 2024, Alcon completed its acquisition of BELKIN Vision, enhancing its glaucoma treatment portfolio. The acquisition included a Direct Selective Laser Trabeculoplasty (DSLT) device, which is designed to provide a minimally invasive option for managing intraocular pressure in glaucoma patients. This move aimed to strengthen Alcon’s position in the growing MIGS market.
• In November 2023, J&J Surgical Vision, Inc. and Alcon, Inc. reached an agreement to settle their pending legal proceedings involving femtosecond laser-supported cataract surgery instruments.
• In August 2023, Glaukos Corporation acquired FDA 510(k) clearance for its product, iStent Infinite. The device is used as a solo method to reduce increased intraocular pressure (IOP) in patients with primary open-angle glaucoma.

Report Coverage:

By Device Type

• Stents
  • Intraocular stents
  • Ab-interno stents
• Implants
  • Trabecular implants
  • Suprachoroidal implants
• Laser Systems
  • Selective laser trabeculoplasty (SLT)
  • Other laser devices
• Goniotomy Devices

By Target

• Trabecular Meshwork Bypass
• Suprachoroidal Space
• Subconjunctival Space
• Schlemm’s Canal
• Others

By Glaucoma Type

• Primary Open-Angle Glaucoma (POAG)
• Angle-Closure Glaucoma
• Secondary Glaucoma
• Normal Tension Glaucoma
• Others

By End-User

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Specialty Clinics

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Alcon
• AbbVie (Allergan)
• Glaukos Corporation
• Santen Pharmaceutical
• Bausch + Lomb
• Microsurgical Technology (MST)
• Sight Sciences
• Aerie Pharmaceuticals
• Lumenis
• Eyenovia
• Oraya Therapeutics
• Katalyst Surgical
• InspireMD
• Karl Storz
• SurgiCare

Frequently Asked Questions (FAQs)